Type 1 Diabetes Exaggerates Features of Alzheimer's Disease in APP Transgenic Mice

Overview

Journal Exp Neurol

Specialty Neurology

Date 2009 Nov 26

PMID 19931251

Citations 75

Authors

Corinne G Jolivalt

Rosemarie Hurford

Corinne A Lee

Wilmar Dumaop

Edward Rockenstein

Eliezer Masliah

Affiliations

Soon will be listed here.

Abstract

A number of studies suggest an association between Alzheimer's disease (AD) and diabetes: AD patients show impaired insulin function, whereas cognitive deficits and increased risk of developing AD occur in diabetic patients. The reasons for the increased risk are not known. Recent studies of disturbances in the insulin-signaling pathway have revealed new perspectives on the links between AD and Type 1 diabetes with a particular focus on glycogen synthase-kinase-3 (GSK3). We have therefore characterized a mouse model of combined insulin-deficient diabetes and AD and find that diabetes exaggerated defects in the brain of APP transgenic mice. Mice with combined APP overexpression and diabetes showed a decreased insulin receptor activity and an increased GSK3beta activity. Concomitantly, tau phosphorylation and number of Abeta plaques, the two pathologic hallmarks of AD, were increased in the brain of diabetic-APP transgenic mice. Our results indicate that the pathologic features of AD are exaggerated in the brain of APP transgenic mice that have concurrent insulin-deficient diabetes, and underscore a possible mechanism of brain dysfunction common to AD and diabetes.

Citing Articles

Implications of microbe-derived ɣ-aminobutyric acid (GABA) in gut and brain barrier integrity and GABAergic signaling in Alzheimer's disease.

Conn K, Borsom E, Cope E Gut Microbes. 2024; 16(1):2371950.

PMID: 39008552 PMC: 11253888. DOI: 10.1080/19490976.2024.2371950.

Experimental laboratory models as tools for understanding modifiable dementia risk.

Sinclair D, Canty A, Ziebell J, Woodhouse A, Collins J, Perry S Alzheimers Dement. 2024; 20(6):4260-4289.

PMID: 38687209 PMC: 11180874. DOI: 10.1002/alz.13834.

Fructooligosaccharide (FOS) and Galactooligosaccharide (GOS) Improve Neuroinflammation and Cognition By Up-regulating IRS/PI3K/AKT Signaling Pathway in Diet-induced Obese Mice.

de Paiva I, da Silva R, Mendonca I, Duarte-Silva E, de Souza J, Peixoto C J Neuroimmune Pharmacol. 2023; 18(3):427-447.

PMID: 37382830 DOI: 10.1007/s11481-023-10069-8.

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid.

Raza M, Chhabra K J Vis Exp. 2023; (194).

PMID: 37092835 PMC: 11165353. DOI: 10.3791/65169.

Linking Diabetes to Alzheimer's Disease: Potential Roles of Glucose Metabolism and Alpha-Glucosidase.

Wee A, Nhu T, Khaw K, Tang K, Yeong K Curr Neuropharmacol. 2022; 21(10):2036-2048.

PMID: 36372924 PMC: 10556372. DOI: 10.2174/1570159X21999221111102343.

References

Curb J, Rodriguez B, Abbott R, Petrovitch H, Ross G, Masaki K . Longitudinal association of vascular and Alzheimer's dementias, diabetes, and glucose tolerance. Neurology. 1999; 52(5):971-5. DOI: 10.1212/wnl.52.5.971. View

Rockenstein E, Mallory M, Mante M, Sisk A, Masliaha E . Early formation of mature amyloid-beta protein deposits in a mutant APP transgenic model depends on levels of Abeta(1-42). J Neurosci Res. 2001; 66(4):573-82. DOI: 10.1002/jnr.1247. View

Lester-Coll N, Rivera E, Soscia S, Doiron K, Wands J, de la Monte S . Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease. J Alzheimers Dis. 2006; 9(1):13-33. DOI: 10.3233/jad-2006-9102. View

Xu W, Von Strauss E, Qiu C, Winblad B, Fratiglioni L . Uncontrolled diabetes increases the risk of Alzheimer's disease: a population-based cohort study. Diabetologia. 2009; 52(6):1031-9. DOI: 10.1007/s00125-009-1323-x. View

Steen E, Terry B, Rivera E, Cannon J, Neely T, Tavares R . Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes?. J Alzheimers Dis. 2005; 7(1):63-80. DOI: 10.3233/jad-2005-7107. View

Lee M, Kao S, Lemere C, Xia W, Tseng H, Zhou Y . APP processing is regulated by cytoplasmic phosphorylation. J Cell Biol. 2003; 163(1):83-95. PMC: 2173445. DOI: 10.1083/jcb.200301115. View

Barnes C . Memory deficits associated with senescence: a neurophysiological and behavioral study in the rat. J Comp Physiol Psychol. 1979; 93(1):74-104. DOI: 10.1037/h0077579. View

MacKnight C, Rockwood K, Awalt E, McDowell I . Diabetes mellitus and the risk of dementia, Alzheimer's disease and vascular cognitive impairment in the Canadian Study of Health and Aging. Dement Geriatr Cogn Disord. 2002; 14(2):77-83. DOI: 10.1159/000064928. View

Huang H, Liang K, Chen C, Chen C, Hsieh-Li H . Intrahippocampal administration of A beta(1-40) impairs spatial learning and memory in hyperglycemic mice. Neurobiol Learn Mem. 2007; 87(4):483-94. DOI: 10.1016/j.nlm.2006.11.006. View

10.

Sima A, Li Z . Diabetes and Alzheimer's disease - is there a connection?. Rev Diabet Stud. 2007; 3(4):161-8. PMC: 1828287. DOI: 10.1900/RDS.2006.3.161. View

11.

Perez A, Morelli L, Cresto J, Castano E . Degradation of soluble amyloid beta-peptides 1-40, 1-42, and the Dutch variant 1-40Q by insulin degrading enzyme from Alzheimer disease and control brains. Neurochem Res. 2000; 25(2):247-55. DOI: 10.1023/a:1007527721160. View

12.

Burns J, Donnelly J, Anderson H, Mayo M, Spencer-Gardner L, Thomas G . Peripheral insulin and brain structure in early Alzheimer disease. Neurology. 2007; 69(11):1094-104. DOI: 10.1212/01.wnl.0000276952.91704.af. View

13.

Noble W, Planel E, Zehr C, Olm V, Meyerson J, Suleman F . Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci U S A. 2005; 102(19):6990-5. PMC: 1088065. DOI: 10.1073/pnas.0500466102. View

14.

Grunblatt E, Salkovic-Petrisic M, Osmanovic J, Riederer P, Hoyer S . Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein. J Neurochem. 2007; 101(3):757-70. DOI: 10.1111/j.1471-4159.2006.04368.x. View

15.

Gasparini L, Netzer W, Greengard P, Xu H . Does insulin dysfunction play a role in Alzheimer's disease?. Trends Pharmacol Sci. 2002; 23(6):288-93. DOI: 10.1016/s0165-6147(02)02037-0. View

16.

DeJONG R . CNS manifestations of diabetes mellitus. Postgrad Med. 1977; 61(1):101-7. DOI: 10.1080/00325481.1977.11714510. View

17.

Ott A, Stolk R, Hofman A, Van Harskamp F, Grobbee D, Breteler M . Association of diabetes mellitus and dementia: the Rotterdam Study. Diabetologia. 1996; 39(11):1392-7. DOI: 10.1007/s001250050588. View

18.

Burdo J, Chen Q, Calcutt N, Schubert D . The pathological interaction between diabetes and presymptomatic Alzheimer's disease. Neurobiol Aging. 2008; 30(12):1910-7. DOI: 10.1016/j.neurobiolaging.2008.02.010. View

19.

Braak H, Braak E . Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991; 82(4):239-59. DOI: 10.1007/BF00308809. View

20.

Rockenstein E, Adame A, Mante M, Moessler H, Windisch M, Masliah E . The neuroprotective effects of Cerebrolysin in a transgenic model of Alzheimer's disease are associated with improved behavioral performance. J Neural Transm (Vienna). 2003; 110(11):1313-27. DOI: 10.1007/s00702-003-0025-7. View